Researcher Professor Diana Eccles, of the University of Southampton, said: 'Our study is the largest of its kind, and our findings suggest that younger women with breast cancer who have a BRCA mutation have similar survival to women who do not carry the mutation after receiving treatment.
The research, led by the University of Southampton, concludes that BRCA-mutated breastcancer is no more unsafe or aggressive than any other form of the disease.
A study of 1.8 million women demonstrated an increased risk of breast cancer with hormonal contraceptive use - including combined oral contraception (COC), progestin-only pills (POPs), and intrauterine systems - with a dose-response relationship. This is compared to approximately 12.5 per cent of women in the general population who develop breast cancer in the UK.
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.
In 2013, Hollywood star Angelina Jolie announced she had had both breasts surgically removed as a preventative measure after tests revealed she carried the mutation, despite not having been diagnosed with cancer.
It's good news for people with BRCA1 and BRCA2 mutations that raise their risk of cancer.
"However, our findings suggest that this surgery does not have to be immediately undertaken along with the other treatment".
For this study, researchers followed more than 2,700 women recruited from more than a hundred British hospitals for almost a decade.
Actually, those with a BRCA mutation had slightly higher survival rates for the first two years after diagnosis, in the case of patients with triple-negative breast cancer.
Most of the women lived 10 years; 73 percent of the women with BRCA mutations lived 10 years and 70 percent of women without the mutations did.
The authors note the findings do not apply to older women.
'Decisions about timing of additional surgery to reduce future cancer risks should take into account patient prognosis after their first cancer, and their personal preferences'.
"It can be hard for some patients to decide whether or not to have risk-reducing surgery, typically double mastectomies and removal of ovaries". There was no significant difference in survival at 5 or 10 years. "These risks determine treatment, and knowing that BRCA1 or BRCA2 mutations do not result in a different prognosis might change the therapeutic approach for these risks".
AztraZeneca Executive Vice President and Head of the Oncology Business Unit Dave Fredrickson said: "This new approval for Lynparza makes it the first and only PARP inhibitor approved in metastatic breast cancer, and the only PARP inhibitor approved beyond ovarian cancer".
Legislators say they are close to CHIP deal
The downside: Federal reimbursement for Ohio Medicaid costs is 63 cents per dollar; CHIP reimbursement is 97 cents per dollar. As for those cookies - those will be sent to the local offices of Steve Chabot and Senators Sherrod Brown and Rob Portman.
Netflix Confirm A Sequel To Bright Is On Its Way
Now the sequel (which was brokered to be produced during the production of the initial film) has been officially announced. The film stars Smith as a police officer in an alternate version of Los Angeles where orcs, fairies and magic co-exist.